One Zone Now Carries AB InBev: China Fires Our July Trigger, and We Downgrade to Underperform

Results vs. Consensus

AB InBev is followed on an organic basis, meaning constant currency and constant scope, and the compiled expectations the shares trade on are expressed that way. On that scorecard the third quarter beat on revenue, volume and per-share earnings and landed exactly on the line that matters most. Organic EBITDA growth of 3.9% matched a consensus that had itself been set below the 4% floor of the company's full-year band, so the Street was already braced for a quarter outside the guide. What it was not braced for was the composition of the quarter.

Q3 2026 Scorecard

The revenue beat is real and it is the only line that beat by a wide margin. The EPS beat is real and it came from below the operating line. The EBITDA line, in dollars, missed by $27 million, which is noise, but the organic rate is the more telling number: it is the lowest of the three quarters we have covered, after 5.3% and 5.8%, and the first below the band.

Year-over-Year Income Statement

Per-share growth of 22.4% and constant-currency growth of 13.9% are the company's figures on unrounded amounts. Margin changes in the reported column are computed on unrounded dollars, so they can differ from the rounded margins shown. In the organic column an increase in a cost line is shown as a negative.

The reported profit line ran the opposite way to the second quarter's. In July the headline was inflated by mark-to-market gains on the derivatives that hedge AB InBev's share-based payment programmes and the shares issued in the Grupo Modelo and SAB combinations. This quarter the Euronext share price fell from EUR 72.66 to EUR 65.32 and the same derivatives produced an $800 million mark-to-market loss. That is why basic EPS of $0.81 sits $0.40 below underlying EPS. Neither swing says anything about the brewing business, and over nine months the mark-to-market line is still a $1,233 million gain.

Sequential Comparison

Read down the table and two lines move in opposite directions. Every operating rate decelerated from the second quarter, with volume, beer volume, revenue, EBITDA and EBIT all slower. Every per-share rate accelerated, with constant-currency EPS growth at its highest of the year. The gap between those two sets of lines is the subject of most of this note.

Nine-Month Position

Nine-month organic EBITDA growth of 5.0% is a point below the 6.0% midpoint of the full-year band. Translation supplied $0.28 of the $0.62 nine-month increase in underlying EPS, or 45%.

Revenue

Revenue per hectolitre rose 4.2% on total volumes up 0.4%, and organic revenue grew 4.9%. The per-hectolitre metric excludes US non-beverage activities, so the two components do not compound exactly to the revenue line. The rate per hectolitre held flat with the second quarter, and the composition improved: management sized mix at roughly a quarter to a third of the 4.2%, which puts pure price at roughly 2.9 to 3.2 points and mix at roughly 1.0 to 1.3 points.

The premium tiers that decelerated in July re-accelerated. Above-core beer revenue grew 8.6% against 6.9%, Balanced Choices 19% against 13%, no-alcohol beer 35% against 27%, and the megabrand aggregate 7.7% against 6.2%. Mainstream beer slowed to 2.1% from 2.7%. The exception, and a large one, is Beyond Beer, which slowed to 19% from 44%.

Reported revenue grew 9.1% against organic growth of 4.9%. Translation added $662 million, about 4.4 points of growth, and scope removed $19 million, about 0.1 point.

Margins

Gross margin expanded 20 basis points organically, a sharp slowdown from 99 in the second quarter, and normalized EBITDA margin contracted 34 basis points to 36.1%. The release attributes the contraction to a step-up in sales and marketing investment behind the mega platforms and to commodity cost headwinds, partly offset by overhead discipline. Trailing-twelve-month sales and marketing investment rose to $8.1 billion from $7.9 billion at the half year.

"EBITDA increased by 3.9% with flattish margins, as higher sales and market investments and commodity headwinds were partially offset by disciplined revenue and cost management." — Michel Doukeris, CEO

The word "flattish" is a generous description of 34 basis points. It is the widest organic contraction of the three quarters we have covered, and it came after a second quarter that management had flagged in May as the heaviest marketing quarter of the year. The second-half cost story that the CFO introduced in July as a modest offset to the currency relief has become the main margin story.

Normalized EBIT margin expanded 27 basis points organically, and the reason it moved the other way from EBITDA is depreciation. Organic EBITDA rose $213 million and organic EBIT rose $242 million, which means organic depreciation and amortisation fell $29 million. Reported depreciation rose only 2.1% against reported revenue up 9.1%. This is the third consecutive quarter in which EBIT has outgrown EBITDA by roughly two points, and it is the arithmetic behind the medium-term outlook the company changed in September, discussed below.

EPS

The per-share bridge shows where the 22.4% came from.

Each line is independently rounded to the cent.

The finance line added $0.13, which is 59% of the total increase and more than the EBIT line's $0.18 net of the $0.11 tax increase. The detail is in the release's finance note. Net interest expense fell $75 million, which is durable and reflects lower gross debt and higher cash balances. Pension and accretion interest fell $83 million to $145 million, which is $45 million below the bottom of the $190 million to $220 million per-quarter range the company has guided all year. Other financial results improved $99 million, a line that swings with currency and hedging costs. Two thirds of the finance benefit therefore sits in lines that either revert to guidance or move around by themselves.

Translation's share of the increase fell again, to 36% from 43% in the second quarter and 56% in the first, so the currency complaint we have made all year is weaker than it was. But a different prop has replaced it. Take the finance benefit out after tax, at roughly $0.10 a share, and constant-currency growth from the operating line falls to about 4% to 5%, consistent with organic EBIT up 6.0% and a tax rate that rose 1.8 points.

Segment Performance

AB InBev reports six zones, and this quarter they split into two groups with almost nothing in between. Middle Americas and South America grew EBITDA by double digits with margin expansion. North America, EMEA and Asia Pacific all shrank EBITDA, and the holding-company cost line widened. Middle Americas is now 44.4% of group EBITDA, up from 43.1% in the second quarter, and Asia Pacific has fallen to 5.7% from 8.3%.

Zone EBITDA sums to $5,956 million against the group's $5,957 million because of rounding. The holding-company line carries central costs and is negative by construction. Its (54.0)% organic figure means the loss widened by $73 million organically, an amount equal to roughly a third of the group's entire organic EBITDA increase.

Where the organic growth came from

This is the table that changed our rating. Excluding Middle Americas, the group's organic EBITDA fell $112 million on a base of roughly $3.4 billion, a 3.3% decline. Excluding Asia Pacific instead, the group grew about 6%. The company's "diversified footprint" argument holds in the sense that one region offset several others. It does not hold in the sense investors usually mean it, which is that growth is spread out.

Middle Americas

An exceptional quarter by any standard. Volumes grew 7.3%, revenue 12.1% and EBITDA 15.6%, with 151 basis points of margin expansion on a margin that was already above 50%. Mexico grew revenue by high-single digits on mid-single-digit volume growth, with low-teens EBITDA growth and margin expansion. Colombia grew revenue by mid-teens on record third-quarter volumes and EBITDA by high-teens. Peru grew volumes by low-teens and Ecuador by mid-teens, both to third-quarter records, and the Dominican Republic also set a record.

"This was boosted by a very good weather. You remember that we talked a lot about the bad weather last year in March, so this year was the opposite of that. We had some tailwinds coming from the comps and the weather." — Michel Doukeris, CEO

Management was candid that weather and an easy comparison helped, and equally clear that the underlying consumer in the region is the healthiest in its footprint, with inflation moving in the opposite direction to Europe, Asia and North America. The CFO added that Peru and Colombia are each now bigger than China and carry higher EBITDA margins.

Assessment: the operating performance is outstanding and it is the reason the group still grew. It is also the concentration risk in owning BUD, and this quarter made it explicit. A zone producing 44.4% of EBITDA and 153% of organic EBITDA growth, on a weather tailwind and an easy base, has to keep doing so for the group algorithm to work. The base gets harder from here.

North America

Volumes fell 2.5%, revenue 0.9% and EBITDA 3.5%, with margin down 93 basis points to 34.1%. In the United States revenue fell 1.2%, revenue per hectolitre rose only 1.5%, sales to retailers fell 3.1% and sales to wholesalers fell 2.7%, and EBITDA fell 4.0%. Canada grew revenue by low-single digits on low-single-digit volume declines and remains the leading share gainer in beer and Beyond Beer.

The share data remain good: ten consecutive quarters of total-alcohol share gains, Michelob Ultra and Busch Light the top two volume share gainers in the industry, and Michelob Ultra Zero the leading share gainer in no-alcohol beer. Management attributed the EBITDA decline to World Cup costs, as the US hosted the tournament, and to unhedged transport costs driven by diesel.

Assessment: share gain inside a shrinking box, and the box shrank faster. The third quarter carried the July 4 shift that management said in July had moved into it, and depletions still deteriorated by 120 basis points. Revenue per hectolitre has now slowed from 4.4% to 3.3% to 1.5% across three quarters, which matters more than the volume line, because pricing power was the part of the US case that was still working.

South America

Revenue grew 9.1% on volumes up 0.8%, and EBITDA grew 13.8% with 135 basis points of margin expansion. Brazil grew revenue 5.3%, with total volume up 1.4%, beer volumes up 0.5% and non-beer up 3.6%, and EBITDA grew 6.1% with 26 basis points of margin expansion. Argentina's volumes fell by mid-single digits and its revenue grew by strong double digits on pricing.

Brazilian beer volume growth of 0.5% sits against an industry that Nielsen measured as growing sales to consumers by mid-single digits, a gap that management attributed to the timing difference between production data and sell-out data around the World Cup. It expects a better consumer in the fourth quarter on election-season income support, a ban on online gambling and a hotter, drier summer.

Assessment: a solid zone result, but Brazil's beer line slowed to 0.5% from 5.0% in the second quarter, and the explanation offered is a data-cut argument that the fourth quarter has to confirm. The Brazilian tax changes discussed for 2027 are an unsized watch item.

EMEA

Revenue grew 4.0% on volumes up 2.5%, but EBITDA fell 1.4% with margin down 177 basis points, the steepest zone contraction after Asia Pacific. Europe held volumes flat and grew revenue slightly while EBITDA declined by mid-single digits on marketing investment and elevated commodity costs. South Africa set a third-quarter volume record and grew revenue by high-single digits, but EBITDA was flattish on commodity and distribution costs and marketing phasing. Nigeria's beer volumes grew by high-single digits against a soft comparison.

Assessment: the third consecutive quarter in which EMEA EBITDA has underperformed its revenue. In July we called it a zone being run for brand equity rather than current earnings. That remains true, and a 177 basis point margin decline is the price of it, now with commodity inflation on top.

Asia Pacific

Volumes fell 11.0%, revenue 9.5% and EBITDA 22.4%, with margin down 426 basis points to 24.0%. China fell 16.8% on both volume and revenue, with revenue per hectolitre flat, and EBITDA fell 30.5%. South Korea's volumes declined by low-single digits in a soft industry. Organic SG&A in the zone fell 6.8%, which the CFO attributed mostly to sales and marketing.

"Volumes declined by 16.8%, as we managed inventory levels in a challenging industry, which was impacted by abnormal weather and continued weakness in the on-premise channel." — AB InBev, Q3 2026 results release

Assessment: the zone margin has now fallen 289, 269 and 426 basis points in successive quarters. The arithmetic damage is contained because the zone is only 5.7% of group EBITDA. The strategic signal is not contained: the company cut sales and marketing in the zone where it says it is investing to recover share. That is a rational response to a destocking quarter, and it is not consistent with the recovery narrative.

Key KPIs

The brand engine and the market engine are telling different stories. Every premium and Balanced Choices measure improved on the second quarter, and the global brands outside their home markets had their best quarter of the year. The market-level measures that matter for the US and China all worsened. The first set supports the long-term thesis. The second set determines the next four quarters of earnings.

Key Topics & Management Commentary

Overall Management Tone: Management was polished and on-message, and it framed the quarter as consistent compounding across different operating environments, language carried straight over from the September Capital Markets Day. On China the posture moved from July's open concession to a technical explanation built on industry data and inventory mechanics, which was more informative and less self-critical. Analyst pushback was again mild, and the one question that pressed on the arithmetic of the fourth quarter received a reaffirmation rather than a bridge.

1. One zone carried the group

Middle Americas added $325 million of organic EBITDA in a quarter in which the group added $213 million. South America added $121 million. Every other line subtracted: Asia Pacific $102 million, the holding-company cost line $73 million, North America $46 million and EMEA $12 million. Excluding Middle Americas, organic EBITDA fell 3.3%.

"Our geographic footprint and global scale continue to enable us to deliver consistent results across different operating environments. Our footprint is both well-diversified and balanced." — Michel Doukeris, CEO

The footprint did deliver a consistent group result, which is the point management was making. The problem is the definition of balanced. Three of the five operating zones shrank EBITDA, and two of them, North America and Asia Pacific, together produce 27.4% of group EBITDA and 31.6% of revenue.

Assessment: diversification worked as insurance this quarter, and insurance is not the same thing as a growth engine. We had argued in July that Middle Americas had quietly become the stock's centre of gravity. This quarter it became the stock's only growth engine, which leaves the group's earnings algorithm dependent on one region continuing to post double-digit growth against harder comparisons.

2. China: the third consecutive deterioration

China volumes fell 1.5% in the first quarter, 9.7% in the second and 16.8% in the third. EBITDA fell 11.8%, 16.1% and 30.5%. Management's explanation this time was more precise than in July. It put the national industry decline at 8% to 9%, its own footprint's industry decline at more than 10% because of exposure to the east coast and to severe summer weather, and said most of the company's decline came from the industry and from reducing channel inventories.

"Majority of the decline in China was industry and inventories driven, while we continued to underperform in sales to consumers, this industry that was very negative." — Michel Doukeris, CEO

Management also put a number on market share: share was down by "one point something" at the start of the year and by less than half a point in the third quarter. And it gave the first dated objective we have heard on China.

"But we are planning, and we're working very hard to get to the end of this year with normal inventories in China. That's our objective." — Michel Doukeris, CEO

At the September Capital Markets Day, the tone was harsher than anything said on an earnings call.

"We should be acting, we should have acted, and now we are running after this adaptation on the portfolio, on the channels, on the geographies." — Michel Doukeris, CEO, Capital Markets Day

Assessment: the inventory explanation is credible and it cuts both ways. If channel destocking is complete by December, the second and third quarters of 2027 lap very weak bases and the reported decline narrows sharply. But destocking is a symptom of sell-out running below plan, and the company admits it is still underperforming sell-out in an industry down north of 10% in its footprint. Our July note said a third consecutive quarter of Chinese deterioration would move the rating. It has, and the inventory objective does not change that, because it is a target for the decline to stop, not for the business to recover.

3. The US got worse in the quarter that held July 4

In July management attributed the second quarter's weak depletions partly to the July 4 holiday falling into the third quarter. The third quarter received that shift and sales to retailers still fell 3.1%, against (1.9)% in the second quarter and +0.3% in the first. Shipments ran 40 basis points ahead of depletions in the quarter, and the nine-month gap has closed to 40 basis points from 90 at the half year, so the catch-up management described is largely done.

"Sales-to-retailers (STRs) declined by 3.1%, estimated to have outperformed a soft industry." — AB InBev, Q3 2026 results release

Revenue per hectolitre slowed to 1.5% from 3.3%, which the release attributes to revenue management and brand mix. EBITDA fell 4.0%. Asked to split the EBITDA decline between World Cup marketing and cost inflation, management described both as large and sized neither.

Assessment: the US case is now a volume problem and a pricing problem at the same time. The World Cup cost is non-recurring and will drop out next year. The transport cost is cyclical and partly unhedged. The pricing slowdown is the item without a ready explanation, and in a category with negative volumes it is the one most likely to persist.

4. EBITDA below the band, EBIT above it, and a new yardstick

Organic EBITDA grew 3.9%, below the 4% floor of the FY26 band. Organic EBIT grew 6.0%, comfortably inside the 5% to 9% band the company adopted as its new medium-term outlook in September. The difference is depreciation, which fell $29 million organically in the quarter after net capital expenditure was cut from $5.5 billion in 2021 to $3.6 billion in 2025.

"By definition, depreciation is a lagging indicator. There was always some delay, so you still have some benefit on depreciation." — Fernando Tennenbaum, CFO, Capital Markets Day

The CFO's own description of depreciation as a "lagging indicator" of which "you still have some benefit" is a description of a finite effect. EBIT has outgrown EBITDA by 180, 220 and 210 basis points in the three quarters of 2026. That is the spread that lifts a 4% to 8% EBITDA business into a 5% to 9% EBIT business.

Assessment: the case for EBIT as the better measure of a business focused on capital efficiency is sound, and we do not dispute it in principle. The timing is awkward. The company changed its headline metric one quarter before the old metric printed below its band, and the new metric is helped by a depreciation tailwind that management itself describes as lagging. We will track both measures, and our model will not credit the EBIT band with more than the depreciation runway we can see.

5. The Capital Markets Day reset the medium-term outlook

The September event in St. Louis marked what management calls the move from the "reset" phase of its ten-year plan to a "reignite" phase. The financial content was a new medium-term outlook, a restated capital structure target and a rebalancing of capital allocation away from deleveraging. FY26 guidance was left unchanged and FY27 guidance will come with the full-year results in February.

"Our new medium-term outlook is for consistent compounding EBIT growth of 5%-9% on average, reflecting the progress we have made in building the earnings power and capital efficiency of the business." — Fernando Tennenbaum, CFO, Capital Markets Day

The CFO also restated an optimal capital structure of around 2 times net debt to EBITDA, against 2.87 times at the end of 2025, and said M&A now complements organic growth rather than being the foundation of the strategy. The near-term priorities he listed were to fund growth fully, raise the dividend progressively, complete the current buyback and strengthen the balance sheet further. The ADR moved 0.3% and (1.5)% across the two event sessions, which suggests the market took the new outlook as a relabelling rather than an upgrade.

Assessment: the dividend increase this quarter is the first concrete expression of the rebalancing, and it is welcome. The outlook change is the part to watch. A 5% to 9% EBIT band sits one point above the 4% to 8% EBITDA band it replaces, and this year the depreciation spread has been worth about two points. While depreciation keeps falling, the new band is easier to meet than the old one. The test is whether EBIT stays inside it once depreciation stops falling.

6. What built the 22% EPS increase

Of the $0.22 increase in underlying EPS, the EBITDA line contributed $0.20, depreciation took $0.02 back, the finance line added $0.13, tax took $0.11 and associates and minorities added $0.02. Translation is spread across those lines and totals $0.08.

"Of course, this year you had some tailwinds from effects on your EPS. But even without the effects, we are growing at 13.9% at constant currency, which tells a lot about the efforts that we are doing to optimize our business." — Fernando Tennenbaum, CFO

The 13.9% is accurate and it deserves a qualification. The finance line's $257 million improvement included $83 million from pension and accretion interest, which printed below its guided range, and $99 million from other financial results, which move with currency and hedging costs. Neither was explained on the call or in the release.

Assessment: the quality of the EPS growth has changed shape rather than improved. Translation now accounts for 36% of the increase, down from 56% in the first quarter, and that part of our bear point has weakened. The finance line now does more of the work than translation does, and if pension and accretion interest returns to the guided range in the fourth quarter, it removes roughly $0.02 to $0.04 a share, before tax, from the run rate.

7. The interim dividend nearly tripled

The board approved an interim dividend of EUR 0.40 per share for FY26, against EUR 0.15 for FY25, an increase of 167%. At the 29 October exchange rate that is about $0.45 per ADR, payable 16 December. Together with the EUR 1.00 FY25 final dividend, the trailing declared dividend is EUR 1.40, a 2.0% yield on the ADR close.

"We announced this dividend, this interim dividend with 40 euro cents, which compares to 15 euro cents in 2025. I think this is, at the end of the day, consistent with our stated ambition of a progressive dividend over time." — Fernando Tennenbaum, CFO

Asked whether the increase is a shift of payment between the interim and the final or a higher full-year payout, the CFO restated the progressive dividend ambition and did not choose.

Assessment: the clearest positive in the print for the capital-return pillar. Whether it is a reallocation or an increase will only be visible when the final dividend is proposed in February. Either way it is cash returned to shareholders, which was the part of the capital story that had weakened most in July.

8. The buyback, and a correction to our own record

The $6 billion programme reached $2.6 billion at 26 October, against $1.9 billion at 24 July. That is $0.7 billion in 94 days, or roughly $2.7 billion annualised, a pace 25% faster than the second quarter's.

"We also continue to execute on the 24-month, $6 billion share buyback program announced last year. To date, we have repurchased $2.6 billion of shares." — Fernando Tennenbaum, CFO

A correction is owed here. Our May and July notes said the programme had no completion date. That was wrong. The October 2025 announcement stated that the programme was to be executed within 24 months, which means by roughly the end of October 2027. The programme is 49% of the way through its window and 43% complete. Finishing on time requires $3.4 billion in about a year, a pace roughly 24% faster than the latest quarter's.

Assessment: the pace improved and the commitment is firmer than we had described. The programme is still behind a straight-line schedule, and management told the Capital Markets Day that completing it is the focus. Fourth-quarter progress is the test of that statement.

9. Premiumisation re-accelerated and Beyond Beer slowed

The premium engine that slowed in July picked up again. Above-core beer grew 8.6%, Balanced Choices 19%, no-alcohol beer 35%, megabrands 7.7%, and Corona grew 20% outside Mexico. Michelob Ultra grew 50% outside the US, and management said 60% of the brand's global growth came from outside the US, up from 40% in the second quarter.

"Used to be less than 1% of our business. Today is more than 1.5%, approaching 2% on a run rate, and the growth rates are very good across the globe, double digits in most every market." — Michel Doukeris, CEO

Beyond Beer went the other way. Group revenue growth slowed to 19% from 44%, and in the US to low-teens from the mid-seventies, with Cutwater at high-thirties against triple digits in July.

Assessment: the mix pillar is back on track at the group level, and the no-alcohol sizing, now approaching 2% of the business, is a useful new disclosure. The Beyond Beer slowdown is large enough to matter to the US case, because Beyond Beer was the US growth driver that still worked. Nobody asked about it, and management did not volunteer an explanation.

10. A third positive volume quarter, and the first negative beer quarter

Total volumes grew 0.4%, the third consecutive positive quarter after eight negatives from 1Q24 to 4Q25. But beer volumes fell 0.1%, after +1.2% and +1.1%, and the total was held up by non-beer volumes growing 4.0%. Record third-quarter volumes in 15 markets did not offset an 11.0% volume decline in Asia Pacific.

"Beer volumes were flattish as growth in two-thirds of our markets was offset by a challenging industry in China." — Michel Doukeris, CEO

Assessment: the volume pillar survived on a technicality. The decline that ended in the first quarter was a beer-volume decline, and beer volume is negative again, entirely because of China. Excluding Asia Pacific, volumes grew in every operating zone except North America. The fourth quarter, with no calendar assist in either direction and China still destocking, is the clean test.

11. Costs did not get easier in the second half

In February management guided to a cost base skewed toward the first half. In July it disclosed unhedged energy and logistics pressure in the second half. This quarter it said costs are now more balanced across the halves, and commodity, transport and distribution costs appeared in the explanation of EBITDA in the US, Europe and South Africa.

"But if you look at the current market prices and kind of knowing that we have this 12-month hedge policy, so we are pretty much not 100%, but almost fully hedged for next year, you have some sort of visibility, and it is looking like more of a normal year." — Fernando Tennenbaum, CFO

Assessment: "a normal year" for 2027 costs is the most useful forward-looking statement on the call, and it comes from a nearly complete hedge book. It also comes from a team whose description of 2026 cost phasing has shifted twice since February. We read it as no relief in 2027 rather than as a tailwind.

12. Grading the commitments from July

Our July note closed with eight forward commitments. Here is where each stands.

Assessment: one delivered, two partly addressed, four went the wrong way and one is pending. The two that went most clearly wrong are China and the US consumer, which are the two bear points that carry our rating.

Guidance & Outlook

The FY26 outlook text is word-for-word identical for the fourth consecutive release, including its reference to "our medium-term outlook of between 4-8%," a month after the Capital Markets Day replaced that outlook. Asked directly whether the second half would still be balanced with the first, given that this requires a step-up in the fourth quarter, the CFO said it still holds.

"Just repeating what we said in Q1, we said that this year would be more or less balanced between first half and second half. I think, given what we are looking in the market, it still holds." — Fernando Tennenbaum, CFO

Implied fourth-quarter ramp: nine-month organic EBITDA growth of 5.0% leaves the full year needing roughly 1.3% in the fourth quarter to reach the 4% floor, 8.9% to reach the 6% midpoint and 16.6% to reach the 8% top. A second half "balanced" with the first, at the half-year rate of 5.6%, needs about 7.3% in the fourth quarter. The fourth-quarter comparison is soft, since 4Q25 organic EBITDA grew only 2.3%. We assume about 5%, which puts the year at about 5.0%.

Street at: the post-print commentary suggested the EPS beat added a little over 1% to full-year consensus. That is an EPS revision. Nothing in the coverage we reviewed moved full-year EBITDA expectations toward the midpoint of the band.

Guidance style: unchanged and uninformative. A band that implies anything from 1.3% to 16.6% for the final quarter of the year is not guidance in the conventional sense. Management's "balanced year" phrase is the real guide, and it now implies a fourth quarter nearly twice as strong as the third.

Analyst Q&A Highlights

Seven analysts asked questions. China drew one full turn and a follow-up on Asia Pacific costs, costs drew two, and the fourth-quarter step-up drew one. Nobody asked about the Beyond Beer slowdown, the finance-line benefit or the widening holding-company loss.

How much of the China decline is weather, and when the destocking ends

The most informative exchange of the call. The question asked for a split between weather and the underlying consumer and for a date on destocking. Management gave the industry decline by source, a share figure and an inventory objective, and conceded continued underperformance in sell-out.

Q: "Can you help us disaggregate how much of that is weather-related versus underlying consumer? Do you think the destocking will be done by the end of this fiscal year?"
— Sanjeet Aujla, UBS

A: "A drop in the industry like 10% will push you to get inventories two to three days down in a month. You know that this is another big component on your shipments, which is, after all, what we report. Majority of the decline in China was industry and inventories driven, while we continued to underperform in sales to consumers, this industry that was very negative."
— Michel Doukeris, CEO

Assessment: the answer explains the size of the shipment decline better than any previous China answer, and the objective of normal inventories by year end is the first dated commitment. It does not split weather from demand, and the share loss is still a loss. A shipment decline driven by destocking ends, while a sell-out decline in a falling industry may not.

Whether the second half is still balanced, given what it requires of the fourth quarter

The only question on the call that tested the guide arithmetically. The question pointed out that a balanced year implies a fourth-quarter step-up and asked for the puts and takes. The answer reaffirmed the framing and gave no bridge.

Q: "Fernando, at the Q2 stage, you talked about a relatively balanced year in terms of EBITDA growth from 1H to 2H. Is that still your expectation with just one quarter to go? Because it implies a step up in Q4. Can you talk about the puts and takes as you see it for 4Q?"
— Mitch Collett, Deutsche Bank

A: "Of course, you have puts and takes, but, then again, business is resilient. We continue to be proactive in revenue management and cost management, so it still holds."
— Fernando Tennenbaum, CFO

Assessment: a reaffirmation without a bridge, on a question that asked specifically for one. On our arithmetic the statement requires about 7.3% organic EBITDA growth in the fourth quarter, against 3.9% in the third. The soft comparison helps. It does not obviously help by three and a half points.

The cost outlook into the fourth quarter and 2027

A direct question on how the cost outlook has changed since the start of the year and whether the operating levers are enough. The answer confirmed the costs had moved from first-half-weighted to balanced, and offered the first read on 2027.

Q: "My first question is on the cost outlook. It has changed a lot since the beginning of the year. So I was wondering if you could touch on the incremental pressures that you are seeing going into Q4 and 2027, and how comfortable are you that you have the operating levers to deal with that environment and still hit your medium-term guidance?"
— Robert Ottenstein, Evercore ISI

A: "So our expectation is for the cost to be more balanced between half one and half two. I think this is true since. So we are seeing, and this is what we saw in Q3, that costs were more balanced between half one and half two."
— Fernando Tennenbaum, CFO

Assessment: an honest confirmation that the cost relief promised in February did not arrive. The 2027 read of "a normal year," from an almost complete hedge book, is useful. It is also not a tailwind, and our FY27 estimate assumes none.

What drove the US EBITDA decline

The question asked for a split between World Cup marketing and input-cost and transport inflation. The answer named both and sized neither, and identified diesel as the transport driver.

Q: "could we go back to the EBITDA decline that you had in the U.S. in Q3, and how much of a drag was actually linked to the extra marketing investments related to the World Cup versus the input cost inflation and transportation cost that you mentioned?"
— Olivier Nicolai, Goldman Sachs

A: "The U.S., as a host of FIFA, had costs linked to that. Mega platform, very important for the business globally, but also for the U.S. This cost is a big component on the Q3. The U.S. is also having costs related to unhedged commodities. The simplest one for you to understand is transportation, because of oil, diesel costs."
— Michel Doukeris, CEO

Assessment: the World Cup cost is the reassuring half, since it does not recur. Without a size, we cannot tell how much of the 4.0% US EBITDA decline is one-off. The answer did not address the slowdown in US revenue per hectolitre, which no cost explanation covers.

How much of revenue per hectolitre is mix

Asked whether the mix contribution was similar to the roughly one point of the first half, management gave a proportion rather than a number.

Q: "I was just wondering, what was the mix component within revenue per hectoliter in Q3? Is it similar to the 1% you had in H1?"
— Olivier Nicolai, Goldman Sachs

A: "In a way you can say that 25% to one third of the revenue per hectoliter is a contribution from mix of premiumization, mix of the right categories. Think about RTD, non-alcohol and brands. Okay? So 25%-30% is mix, around 70% is pure price rate."
— Michel Doukeris, CEO

Assessment: on 4.2%, that is roughly 1.0 to 1.3 points of mix and 2.9 to 3.2 points of price, consistent with pricing at inflation. It confirms the mix pillar is intact and contributing about a point, which is what the first half delivered.

Whether a competitor pricing below inflation changes the industry

The question cited a large competitor's statement the previous day that it would price below consumer inflation, and asked whether the industry pricing environment is changing. Management restated its policy of pricing in line with inflation and argued that the industry still has margin to recover.

Q: "One of your bigger competitors yesterday talked about taking pricing below CPI yesterday. I am conscious that you just said that it is going to be a relatively normal year for COGS, but ABI has always aimed for pricing to be roughly at CPI. Are you seeing any change in the industry pricing environment?"
— Mitch Collett, Deutsche Bank

A: "If you look pre-COVID to post-COVID, the industry took a lot of costs and did not price it all into the price to consumer. The margins are not where they used to be or should be if you just go back to before COVID."
— Michel Doukeris, CEO

Assessment: a confident answer, and one the US data does not support this quarter, where revenue per hectolitre rose 1.5% against group pricing near inflation. If a large competitor prices below inflation in 2027, the US is where the gap is likely to show first.

Whether the dividend increase is a rebalancing or a higher payout

The question asked whether the near-tripling of the interim dividend shifts payment from the final to the interim, or signals a faster rise in the total payout. The answer restated the policy without choosing.

Q: "Should we see today's increase mainly as a rebalancing between interim and final dividend, or does a stronger balance sheet give you? You say it gives you more options, but does it give you scope to accelerate the increase in the overall payout?"
— Andrea Pistacchi, Bank of America

A: "We announced this dividend, this interim dividend with 40 euro cents, which compares to 15 euro cents in 2025. I think this is, at the end of the day, consistent with our stated ambition of a progressive dividend over time."
— Fernando Tennenbaum, CFO

Assessment: a non-answer. The February final dividend will settle it. If the final stays near EUR 1.00, the full-year payout rises about 22%, which is a real step-up rather than a rebalancing.

The shape of the 2027 algorithm, and whether no-alcohol beer can scale

The opening question asked how volume, price and mix would balance in 2027 with commodity pressure building, and whether no-alcohol beer is at a tipping point. Management declined to guide 2027, pointed to the new EBIT outlook and sized no-alcohol beer.

Q: "In 2026, you have got a pretty healthy balance between volumes, price, and mix, and the replicable growth drivers are clearly working. I am not looking for explicit guidance for 2027, but how are you thinking about those three buckets going into next year, especially as there is a bit more commodity pressure sort of creeping in?"
— Edward Mundy, Jefferies

A: "During the Capital Markets Day, we talked about this midterm outlook evolving from EBITDA 4% to 8% to become EBIT 5% to 9% as we now get into what we call the second phase of our 10-year plan."
— Michel Doukeris, CEO

Assessment: the answer moved the reference point from EBITDA to EBIT in the first minute of Q&A, on the day EBITDA printed below its band. The no-alcohol figure, approaching 2% of the business on a run rate, is the substantive disclosure and supports the mix pillar.

What They're NOT Saying

1. How the fourth quarter gets to a balanced year: the CFO reaffirmed a balanced first and second half, which requires about 7.3% organic EBITDA growth in the fourth quarter against 3.9% in the third. No bridge was offered, and the guide was neither narrowed nor cut.
2. Why pension and accretion interest printed $45 million below the guided range: $145 million against a $190 million to $220 million per-quarter guide that was reissued unchanged in the same release. The release gives no explanation, and the line supplied a large part of the EPS beat.
3. Why Beyond Beer slowed to 19% from 44%: in the US the slowdown was to low-teens from the mid-seventies. The call discussed BeatBox integration and spirits competition in general terms, and never addressed the slowdown itself.
4. What widened the holding-company loss by $73 million organically: central costs grew by an amount equal to roughly a third of the group's organic EBITDA increase. The release does not explain it.
5. How much China marketing was cut: Asia Pacific SG&A fell 6.8% organically, which the CFO attributed mostly to sales and marketing, in the same release that says the company continues to invest behind its Chinese megabrands.
6. The size of the World Cup cost in the US: called "a big component" of the US EBITDA decline and not quantified, which leaves the recurring part of the decline unknown.
7. Net debt and leverage at the end of the quarter: AB InBev discloses net debt only at the half year and year end. The CFO pointed instead to trailing free cash flow exceeding any year's bond maturities, which is a refinancing statement rather than a leverage figure.
8. A return figure on the $2.9 billion metal-container buy-in: the Capital Markets Day described it as EPS-accretive and still offered no number.

Market Reaction

• Pre-print setup: BUD closed at $80.98 on 28 October, up 26.5% year to date against the S&P 500's 13.1%, up 31.8% over twelve months and 9.0% over thirty days. The 52-week closing range was $60.01 to $86.48, and the high was set on 31 July, the session after the second-quarter print. The shares fell to $73.02 on 1 October, rallied 17.1% to $85.49 by 22 October, and gave back 5.3% into the print.
• Reaction session: the release landed at 7:00 a.m. CET, before the US open. The ADR opened at $79.50, down 1.8%, traded a range of $77.75 to $79.77, and closed at $79.52, down 1.8% or $1.46.
• Volume: 3.8 million shares against a thirty-day average of 2.1 million, or 1.8 times normal.
• Primary listing: the Brussels line was down 2.7% in early trade, fell as far as EUR 69.64, or 4.65%, and closed at EUR 70.68, down 3.23%. With the euro up 0.24% against the dollar, that is a decline of about 3.0% in dollars, so the ADR closed about 1.2 points better than the European close implied.
• Benchmark and peers: the S&P 500 fell 0.30% and the consumer staples sector ETF rose 1.54%. Among peers, Coca-Cola rose 1.19%, Constellation Brands 0.42% and Boston Beer 0.13%, while Molson Coors fell 0.08%, Heineken's ADR 0.16%, Coca-Cola Europacific 0.16% and Diageo's ADR 0.69%.
• Next session: on 30 October the ADR rose 1.08% to $80.38 and the Brussels line 1.81%, on a day when the S&P 500 fell 1.82%.
• Since our July note: the ADR is down 7.7% from $86.14, against an S&P 500 up 3.8% over the same period.

The 1.8% decline understates how badly the print read on a relative basis. Staples rose 1.54% on the session, so the ADR lagged its own sector by more than three points, and it lagged every peer we track. The Brussels line, which trades the release for a full European session before New York opens, fell more than 3%. There was no read-through to the category: Molson Coors and Heineken were roughly flat on the day.

The rebound on 30 October on a sharply falling index is the bull case's best piece of evidence, and we take it seriously, although the ADR's 1.08% gain still trailed the staples ETF's 1.41%. The most economical reading is that the market sold the composition of the quarter on the day and bought the dividend and the EPS growth on the next. Both readings are defensible. Over the three months since our July note, the market has delivered its verdict on the composition: the shares are down 7.7% in a market up 3.8%.

The pre-print run matters for the reaction. The shares rallied 17.1% in three weeks into late October, then gave back a third of that before the release. Some of the reaction-day decline is that rally unwinding, which is why we place more weight on the three-month relative move than on the single session.

Street Perspective

Debate: Is the growth engine broad enough to justify a compounder multiple?

Bull view: the diversified footprint is the point. The group absorbed a 30.5% fall in Chinese EBITDA, a US decline and a soft Europe and still grew EBITDA, EBIT and EPS. Middle Americas is not a one-quarter story. It has posted record volumes in several markets for three quarters, and the region's consumer has the best fundamentals in the footprint.

Bear view: one zone produced 153% of the quarter's organic EBITDA growth, helped by weather and an easy comparison. The two largest problem markets, the US and China, produce 27% of EBITDA and both deteriorated. A business whose growth depends on one region doing double digits deserves a lower multiple than a business growing everywhere at mid-single digits.

Our take: the bear has the better of this one, and it is the argument behind our downgrade. The bull is right that diversification worked as insurance. Insurance does not earn a growth multiple.

Debate: Does the switch to EBIT make the growth target better or just easier?

Bull view: EBIT is the right measure for a business that has finished deleveraging and is focused on capital efficiency, and the company's capital expenditure reductions are a genuine improvement that EBITDA does not capture. A 5% to 9% EBIT target, delivered consistently, supports double-digit EPS growth with a rising buyback and falling finance costs.

Bear view: the switch came one quarter before EBITDA printed below its band, and EBIT is flattered by a depreciation decline that the CFO calls a lagging effect. Once depreciation stabilises, the EBIT band is the EBITDA band plus a point that has not yet been earned.

Our take: both are partly right. The measure is defensible and the timing is unhelpful. We will judge the new target on the first year in which depreciation is flat, which is not 2027.

Debate: Is China a destocking event or a structural share problem?

Bull view: the industry fell by more than 10% in the company's footprint on extreme weather and on-premise weakness, and most of the company's decline was destocking, which management aims to finish by year end. Market share loss has narrowed to less than half a point. From the second quarter of 2027 the comparison base is very low.

Bear view: this is the third consecutive quarter of deterioration, the company still underperforms sell-out, and it cut sales and marketing in the market it says it is investing to recover. At the Capital Markets Day management said it "should have acted" earlier. An inventory reset is the end of a decline, not the start of a recovery.

Our take: the destocking argument will probably flatter the reported numbers from the second quarter of 2027, and we expect the decline to narrow sharply. That is a comparison effect. The structural question is sell-out share, and on that the evidence is still negative.

Debate: Does the capital return case offset the operating mix?

Bull view: trailing free cash flow of nearly $14 billion is close to a 9% yield on the market capitalisation, the interim dividend nearly tripled, the buyback pace rose 25%, and management has said completing the $6 billion programme is the near-term focus. At about 16 times our FY27 estimate, the shares already discount the slower top line.

Bear view: the free cash flow is consolidated and includes the share attributable to Ambev's minority holders, and part of the first-half increase was working-capital timing. Cash returned to shareholders runs at about 3.7% of the market value, and the rest has gone to debt reduction and acquisitions. The finance-line benefit that drove this quarter's EPS is partly non-recurring.

Our take: this is the strongest argument against our downgrade, and it is why our conviction is moderate. Capital return improved this quarter on every measure. It does not yet offset an operating mix in which only one region is growing.

Model Update

Our July note set FY26 underlying EPS at $4.35 and FY27 at $4.75. The nine months delivered more EPS than that path implied, mostly through the finance line and currency, and less EBITDA growth. EPS goes up and the EBITDA assumption comes down.

FY27 moves to $4.85 from $4.75, which is 9.0% growth on the revised FY26 base. That assumes organic EBIT growth of about 6%, in the lower half of the new 5% to 9% band, flat finance costs, a 27% tax rate, about 1.5% of share-count reduction from the buyback, and zero currency translation. The currency assumption remains the widest source of error in both directions: translation supplied 45% of the nine-month EPS increase.

Valuation at the 29 October close

Enterprise value does not add back minority interests, principally in Ambev, so it understates the full claim on consolidated EBITDA. LTM underlying EPS is FY25's $3.73 less 9M25's $2.78 plus 9M26's $3.40.

Valuation conclusion. We now apply 16 to 17 times our FY27 estimate of $4.85, against 19 to 20 times in May and July, for a twelve-month fair value of $78 to $82. From $79.52 that implies a price return of (1.9)% to +3.1%, or 1.8% to 6.8% including the 3.7% cash return. That is below the range we called market-like in July, and it is why the rating moves.

The multiple cut is the judgement in this note, so the reasons should be explicit. First, the growth engine has narrowed to one region: excluding Middle Americas, organic EBITDA fell this quarter. Second, the two markets that were problems at initiation, China and the US consumer, have deteriorated in each of the three quarters we have covered. Third, this quarter's per-share growth leaned on a finance-line benefit and a depreciation tailwind, both finite. A business compounding broadly at mid-single digits deserves 19 to 20 times. This is a business compounding narrowly, and 16 to 17 times reflects that.

One fact cuts against us and deserves to be stated plainly. The new fair value range sits around the price at which we initiated at Hold in May, $80.37, when we said that level offered 7% to 12% of price upside. The difference is three quarters of evidence on China and the US, and an EBITDA growth rate that has fallen from 5.3% to 3.9% over the same period. The shares are also cheaper than they were in July on the same earnings year: 16.4 times FY27 now against 17.8 times at the July close. The free cash flow yield of 8.8% is the strongest objection to an Underperform rating, and it is the main reason our conviction is moderate rather than high.

Thesis Scorecard Post-Earnings

The pillars below are the same seven established in May, graded against what this quarter's print and call revealed. Status tags carry the notation used in the standing thesis file.

The July rating triggers, graded

In July we let a softer version of the China trigger, written in May, pass as an argument against an upgrade rather than a reason to downgrade. Reading the July trigger the same way would leave it with no consequence at all. The upgrade condition was a conjunction, with all three needed together, and none of the three is fully met. The downgrade condition was a disjunction, with either sufficient, and one has fired.

Overall: the thesis has split. The brand and capital pillars improved: premiumisation re-accelerated, no-alcohol beer is approaching 2% of the business, the interim dividend nearly tripled and the buyback quickened. The market pillars weakened: beer volume turned negative, China fell further, and the US lost both volume and price. One bull pillar moved up and one moved down, and one bear point re-emerged. The operating engine that the rating depends on is now a single region.

Action: Underperform, downgraded from Hold, with a fair value of $78 to $82 and moderate conviction. July's second downgrade trigger, a full-year EBITDA outcome below 6.0%, is on course to fire in February in every outcome our model contemplates. We count it as already reflected in this downgrade, and it will not move the rating again. We set three new triggers, each outside our own estimates, and any one of them takes the rating back to Hold: (1) fourth-quarter organic EBITDA growth of at least 7.3%, the rate management's balanced-year statement requires, against our assumption of about 5%; (2) first-quarter 2027 China volumes better than a 5% decline, against our expectation of a high-single-digit decline, with management confirming that channel inventories have normalised; (3) a share price at or below $74 with our estimates unchanged, where the fair value range would again imply a market-like return. A FY27 EBIT guide in February below the 5% to 9% band would raise our conviction in the downgrade.